Latest Breaking News On - அஜாஸ் ஹுசைன் - Page 1 : comparemela.com

The contract also required Emergent to stand ready to produce up to 50 million doses of vaccine within four months in the event of an influenza pandemic. To show that it was up to the task, Emergent was supposed to work with a company developing a flu vaccine candidate and seek F.D.A. approval to manufacture it by June 2020. As the deadline neared, however, Emergent still had not met the requirement. The vaccine candidate of its chosen partner company had failed in clinical trials, and Emergent had not found a replacement. “Emergent does not have a candidate, strategy or plan for fulfilling the flu requirement,” according to a government document in June 2019. “Emergent needs to make this a priority so they are not in default.”

New yorkUnited statesMajaz hussainNew york timesBiomedical advanced researchDrug administrationDevelopment authorityEmergent biosolutionsபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்அஜாஸ் ஹுசைன்புதியது யார்க் முறைவளர்ச்சி அதிகாரம்வெளிப்படுகிறது உயிர் தீர்வுகள்